NCT00248833View on ClinicalTrials.gov

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 5, 2005

Primary Completion Date

November 30, 2006

Study Completion Date

December 31, 2007

Conditions
Meningitis, Meningococcal, Serogroup B
Interventions
BIOLOGICAL

25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine

The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 25µg with and without adjuvant were administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.

BIOLOGICAL

50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine

The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 50µg without adjuvant was administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.

Trial Locations (1)

20910

Walter Reed Army Institute of Research, Clinical Trials Center, Silver Spring

All Listed Sponsors
collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

U.S. Army Medical Research and Development Command

FED

NCT00248833 - Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis. | Biotech Hunter | Biotech Hunter